FDA Approves New Treatment for Travelers’ Diarrhea
Aemcolo is a broad spectrum, semi-synthetic, orally-administered, minimally-absorbed antibiotic designed to allow for delayed release to the colon.
Aemcolo is a broad spectrum, semi-synthetic, orally-administered, minimally-absorbed antibiotic designed to allow for delayed release to the colon.
The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.
The study aimed to determine whether direct-acting antiviral therapy reduced fibrosis and assessed whether any predictors of treatment failure existed at 1-year follow-up.
The recommendations have been published in the AGA’s official journal, Gastroenterology.
The test works by measuring levels of anti-cytolethal distending toxin B (CdtB) and anti-vinculin, 2 biomarkers of post-infectious IBS-D and IBS-M.
In one study, 86% of patients clinically diagnosed with esophagopharyngeal reflux reported significant reduction in symptoms after 2 weeks of use.
The study included 530 patients, aged 18 to 60 years, with computed tomography-confirmed uncomplicated acute appendicitis.
Results of the study found on-demand PPI use to be superior to daily administration of a PPI (pooled OR: 0.50; 95% CI: 0.35, 0.72).
While several secretagogues have been recently approved by the Food and Drug Administration (FDA), a lack of head-to-head trials led researchers to conduct a systematic review to compare the effectiveness of these agents in patients with IBS-C.
Treatments (NSBB, isosorbide mononitrate, carvedilol, variceal band ligation) were compared as monotherapy or as combination therapy with each other or versus placebo.